Article
C57BL/6 mice pretreated with alpha-tocopherol show a better outcome of trypanosoma cruzi infection with less tissue inflammation and fibrosis
Registro en:
Silva, Amanda C. O et al. C57BL/6 mice pretreated with alpha-tocopherol show a better outcome of trypanosoma cruzi infection with less tissue inflammation and fibrosis. Frontiers in Immunology, v. 13, p. 1-10, 2022.
1664-3224
doi.org/10.3389/fimmu.2022.833560
Autor
Silva, Amanda C. O
Bonfim, Maiara
Fontes, Jonathan L. M
Santos, Washington L. C. dos
Mengel, José
Cardillo, Fabíola
Resumen
Conselho Nacional de Desenvolvimento Científico e Tecnológico (CNPq). Fundação de Amparo à Pesquisa do Estado da Bahia (FAPESB). Fundação de Amparo à Pesquisa do Estado do Rio de Janeiro (FAPERJ). Fundação Octácilio Gualberto (FOG). Chagas disease is accompanied by a multisystem inflammatory disorder that follows Trypanosoma cruzi infection. Alpha-tocopherol has been described as an antioxidant and a potential adjuvant to enhance immune responses to vaccines. Therefore, we have evaluated the immune response to T. cruzi infection upon alpha-tocopherol pre-administration. The results show that administration of alpha-tocopherol before the infection results in lower parasitemia and lower mortality of C57BL/6 mice infected with the Tulahuen T. cruzi strain. Alpha-tocopherol administration in normal C57BL/6 mice resulted in higher levels of IFN-γ production by T and NK cells before and after the infection with T. cruzi. More importantly, previous administration of alpha-tocopherol increased the production of IL-10 by T and myeloid suppressor cells and the formation of effector memory T cells while decreasing the expression of PD-1 on T cells. These results suggest that alpha-tocopherol may limit the appearance of dysfunctional T cells during the acute and early chronic phases of T. cruzi infection, contributing to control infection. In addition, alpha-tocopherol could diminish tissue inflammation and fibrosis in late acute disease. These results strongly suggest that alpha-tocopherol may be a helpful agent to be considered in Chagas disease.
Materias
Ítems relacionados
Mostrando ítems relacionados por Título, autor o materia.
-
Putative Role of the Aldo-Keto Reductase from Trypanosoma cruzi in Benznidazole Metabolism
Garavaglia, Patricia Andrea; Garavaglia, Patricia Andrea; Garavaglia, Patricia Andrea; Garavaglia, Patricia Andrea; Garavaglia, Patricia Andrea; Laverriere, Marc; Laverriere, Marc; Laverriere, Marc; Laverriere, Marc; Laverriere, Marc; Cannata, Joaquin Juan Bautista; Cannata, Joaquin Juan Bautista; Cannata, Joaquin Juan Bautista; Cannata, Joaquin Juan Bautista; Cannata, Joaquin Juan Bautista; Garcia, Gabriela Andrea; Garcia, Gabriela Andrea; Garcia, Gabriela Andrea; Garcia, Gabriela Andrea; Garcia, Gabriela Andrea (American Society for MicrobiologyAmerican Society for MicrobiologyAmerican Society for MicrobiologyAmerican Society for MicrobiologyAmerican Society for Microbiology, 2016-05)Benznidazole (Bz), the drug used for treatment of Chagas' disease (caused by the protozoan Trypanosoma cruzi), is activated by a parasitic NADH-dependent type I nitroreductase (NTR I). However, several studies have shown ... -
Detección de Trypanosoma cruzi en tejido y sangre murina por PCR convencional y en tiempo real
Davies, Carolina; Poma, Hugo Ramiro; Cardozo, Rubén Marino; Mora, Maria Celia; Ramos, Federico; Rajal, Verónica Beatriz; Basombrio, Miguel Angel Manuel (Federación Bioquímica de la Provincia Buenos Aires, 2014-12)El objetivo del presente trabajo fue comparar la detección de ADN de Trypanosoma cruzi mediante PCR en tiempo real (qPCR) y PCR convencional en sangre periférica (n=25) y músculo esquelético (n=20) de ratones tratados ... -
Use of the polymerase chain reaction (PCR) for the therapeutic control of chronic Trypanosoma cruzi infection
Lacunza, Carlos Diego; Negrette, Olga Sánchez; Mora, María Celia; Bustos, María Fernanda García; Basombrío, Miguel Ángel